Prescribing guide
Ultomiris (ravulizumab-cwvz)Meningococcal vaccine requirements, REMS, weight-based dosing, supplemental doses and prior authorization criteria for NMOSDFor prescribers and their offices treating neuromyelitis optica spectrum disorder (NMOSD): what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
REMS-certified prescriber, MenACWY and MenB vaccination completed or updated at least 2 weeks before day 1 or antibacterial prophylaxis with vaccines as soon as possible, counseling with the Patient Safety Card and Patient Guide, and a REMS-certified healthcare setting or pharmacy that verifies prescriber certification and documents vaccination status.
Example PA threshold
Label: adults with NMOSD who are anti-AQP4 antibody positive, 40kg or more. FEP example: age 18 or older, anti-AQP4 antibody positive, no dual therapy with another C5 complement inhibitor for NMOSD, meningococcal vaccination at least 2 weeks before initiation unless treatment cannot be delayed, prescriber enrolled in the REMS.
Monitoring
Meningococcal infection at any time, at least 1 hour of observation after each infusion, revaccination per ACIP for the duration of therapy; no scheduled laboratory test is written into the label for NMOSD.
Support line
Alexion OneSource, 1-888-765-4747, Monday to Friday 8:30 AM to 8 PM ET, CoPay Program as little as $0 for commercial plans, annual maximums may apply, enrollment fax 1-800-420-5150; the label lists the same number for the REMS.
Give your patient their plan
A one-page handout for starting Ultomiris, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/ultomiris-neuromyelitisBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Certify in the ULTOMIRIS and SOLIRIS REMS | Review the Prescribing Information, Healthcare Provider Safety Brochure, Patient Safety Card and Patient Guide, then submit the Prescriber Enrollment Form to the REMS. | FDA REMS page |
| Assess before initiation | Assess for unresolved meningococcal infection and do not initiate if a serious one is unresolved. Assess vaccination status for serogroups A, C, W, Y and B and vaccinate as needed per current ACIP recommendations for complement inhibitor recipients. | FDA REMS page |
| Vaccinate | Complete or update vaccination against Neisseria meningitidis serogroups A, C, W, Y and B at least 2 weeks before the first dose. ACIP's schedule for these patients differs from the vaccine prescribing information, so prior standard vaccination may not meet it. | FDA label |
| Or prophylaxis | If urgent therapy is indicated in a patient not up to date, give antibacterial prophylaxis and the vaccines as soon as possible; the REMS requires the prescriber to write the prophylaxis prescription. The label says optimal regimens and durations have not been studied. | FDA label |
| Counsel and hand over the card | Counsel with the Patient Safety Card and Patient Guide and give the patient copies. The card is carried at all times during treatment and for 8 months after the last Ultomiris dose. | FDA REMS page |
| Pneumococcal and Hib | Section 5.3 notes increased susceptibility to S. pneumoniae and H. influenzae, higher risk in children, and says to vaccinate against S. pneumoniae and Hib per ACIP; the sentence states no age limit, but it directly follows one about children, and the Medication Guide addresses these vaccines for children. Not a REMS element. | FDA label |
| Book a certified site | Healthcare settings and pharmacies that dispense must be certified. Before each dispense they contact the REMS to verify the prescriber is certified. Before the first dose they assess and document meningococcal vaccination status, including prophylaxis if needed, and repeat that for up to 6 months in patients not initially up to date. | FDA REMS page |
| Contraindication | Do not initiate in a patient with unresolved serious Neisseria meningitidis infection. This is the label's only contraindication. | FDA label |
| OneSource enrollment | Online form, email to OneSource@Alexion.com or fax to 1-800-420-5150, with the patient's signature. The form lists NMOSD as a condition; interpreters are available. | OneSource enrollment |
| Access tools | Alexion Access Navigator posts an NMOSD common prior authorization criteria resource, a sample letter of medical necessity, a sample appeal letter, a coding and billing guide, a reauthorization guide and home infusion access considerations. Field Reimbursement Managers are reached through 1-888-765-4747. | Alexion Access Navigator |
| CoPay Program | Commercial insurance only, enrolled in OneSource, FDA-approved indication, US or territories; as little as $0, annual maximums may apply. Excludes Medicare, Medicare Advantage, Medigap, Medicaid, VA, DoD and TRICARE. Massachusetts and Rhode Island residents get medication but not infusion cost help. | CoPay terms |
Prior authorization criteria and what to document
One public policy as the example: Blue Cross Blue Shield Federal Employee Program, July 1, 2026. Approval six months at first, then 12 months at a time on renewal. Renewal asks for fewer relapses on Ultomiris, no unacceptable toxicity and continued REMS enrollment. This policy was approved on June 11, 2026 and cites the September 2025 label. It predates the October 2026 label, which added IgA nephropathy as a use. The NMOSD use it describes matches the current label. It still uses the old program name, Ultomiris REMS, from before March 2024. It is here as an example of what a plan asks for, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Diagnosis | Neuromyelitis optica spectrum disorder, age 18 or older | Diagnosis in the note | FEP Blue policy |
| Serology | Anti-aquaporin-4 (AQP4) antibody positive | Antibody result with date | FEP Blue policy |
| No dual therapy | No dual therapy with another prior authorization C5 complement inhibitor for NMOSD; Appendix 4 lists Soliris and Ultomiris | Medication list; for a switch, the last eculizumab dose date | FEP Blue policy |
| Vaccination | Vaccination against Neisseria meningitidis at least 2 weeks prior to initiation, unless treatment cannot be delayed | Vaccine names and dates, or the prophylaxis prescription | FEP Blue policy |
| REMS | Prescriber enrolled in the REMS; the policy still uses the old name Ultomiris REMS | Enrollment confirmation | FEP Blue policy |
| Approval duration | Six months initially, 12 months on renewal; the policy cites the September 2025 package insert | Calendar the renewal ahead of the next 8-week dose | FEP Blue policy |
| Renewal | Fewer relapses while on Ultomiris, absence of unacceptable toxicity, no dual C5 therapy, prescriber still enrolled in the REMS | Relapse history since start | FEP Blue policy |
| Trial population | Study ALXN1210-NMO-307 enrolled 58 adults with a positive anti-AQP4 serologic test, at least 1 relapse in the prior 12 months and EDSS of 7 or lower; registered as NCT04201262 | Relapse dates and EDSS, for a letter of medical necessity | ClinicalTrials.gov |
Ultomiris dosing and titration
| When | Label | Source |
|---|---|---|
| Day 1, loading | 40 to under 60kg: 2,400mg. 60 to under 100kg: 2,700mg. 100kg or more: 3,000mg. Diluted to 50mg/mL in 0.9% sodium chloride, through a 0.2 or 0.22 micron filter; minimum infusion 0.8, 0.6 and 0.4 hours, maximum rate 60, 90 and 150mL/hr respectively. | FDA label |
| Day 15, first maintenance | 3,000mg, 3,300mg or 3,600mg by the same weight bands; minimum infusion 0.9, 0.7 and 0.5 hours, maximum rate 67, 95 and 144mL/hr. The 7-day window does not apply to this dose. | FDA label |
| Every 8 weeks | Maintenance dose every 8 weeks from day 15. Occasional variation within 7 days of the scheduled day is allowed; subsequent doses return to the original schedule. | FDA label |
| Switching from eculizumab | Loading dose at the time of the next scheduled eculizumab dose; first maintenance dose 2 weeks after the loading dose (Table 2). | FDA label |
| After each PE or PP session | Within 4 hours. 40 to under 60kg: 1,200mg if the most recent dose was 2,400mg, 1,500mg if 3,000mg. 60 to under 100kg: 1,500mg if 2,700mg, 1,800mg if 3,300mg. 100kg or more: 1,500mg if 3,000mg, 1,800mg if 3,600mg (Table 3). | FDA label |
| After an IVIg cycle | 600mg within 4 hours following completion of the cycle, for every weight band of 40kg or more (Table 3). Table 6 gives minimum infusion times for supplemental doses, from 0.17 to 0.5 hours. | FDA label |
| Missed dose | The patient should contact the healthcare provider immediately. | FDA label |
| Preparation and stability | Administer immediately after dilution. If not, refrigerate at 2 to 8°C for no more than 24 hours including infusion time, then give within 4 hours of removal. Let the admixture reach room temperature in ambient air only. | FDA label |
| Vials | 300mg/3mL (NDC 25682-025-01) and 1,100mg/11mL (NDC 25682-028-01) single-dose vials, one per carton; refrigerate at 2 to 8°C in the carton, do not freeze or shake. | FDA label |
| Pediatric and geriatric | Safety and effectiveness in pediatric patients with NMOSD have not been established. The NMOSD trial included 7 patients aged 65 or older, too few to assess differences. | FDA label |
Monitoring the Ultomiris label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Before day 1 | Meningococcal vaccination status against the ACIP complement inhibitor schedule; unresolved serious N. meningitidis infection | Required by the label and the REMS; prophylaxis prescription if urgent; initiation contraindicated with unresolved serious infection | FDA label |
| Each infusion | Infusion-related reactions: lower back or abdominal pain, muscle spasms, drop or rise in blood pressure, rigors, limb discomfort, hypersensitivity, dysgeusia; anaphylaxis reported postmarketing | Observe at least 1 hour after completion; slow or stop at the physician's discretion, interrupt for cardiovascular instability or respiratory compromise. Reported in about 1 to 8% across trials, 7% in the NMOSD trial | FDA label |
| Any time | Meningococcal infection: fever, fever with tachycardia, headache with fever, confusion, myalgia with flu-like symptoms, fever with rash, headache with nausea or vomiting, headache with stiff neck or back, photophobia | Evaluate immediately; consider interrupting Ultomiris during treatment of serious meningococcal infection, weighing the risk of interruption in the disease being treated | FDA label |
| Per ACIP | Meningococcal revaccination | Revaccinate considering the duration of therapy; vaccination does not eliminate risk | FDA label |
| Ongoing | Other Neisseria and encapsulated bacterial infections, including disseminated gonococcal infection | Use caution with any other systemic infection; counsel on gonorrhea prevention and regular testing for patients at risk | FDA label |
| NMOSD trial safety | COVID-19 24%, headache 24%, back pain 12%, urinary tract infection 10%, arthralgia 10%, pyrexia 9%, cystitis 9%, upper respiratory tract infection 9%, dizziness 7%, infusion-related reaction 7% | 58 adults, open label, no concurrent placebo arm; serious adverse reactions in 8 patients (13.8%) | FDA label |
| NMOSD trial efficacy | No adjudicated on-trial relapses over a median 73.5 weeks; hazard ratio 0.014 (95% CI 0.000 to 0.103) against the external placebo arm of Study ECU-NMO-301 | Baseline concomitant immunosuppressant use 48% on Ultomiris and 72% in the external placebo group; median historical relapses 2 and 4 | FDA label |
| After stopping | Patient Safety Card carried for 8 months after the last dose; breastfeeding avoided for 8 months after the final dose | The label's discontinuation monitoring periods are written for PNH and aHUS, not NMOSD | FDA label |
Ultomiris drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| Plasma exchange, plasmapheresis, IVIg | Reduce serum ravulizumab concentrations and require a supplemental dose within 4 hours (Table 3) | FDA label |
| Neonatal Fc receptor blockers | Agents such as efgartigimod may lower systemic exposure and reduce effectiveness; closely monitor for reduced effectiveness | FDA label |
| Concomitant immunosuppressants | The NMOSD trial allowed stable corticosteroids, azathioprine, mycophenolate mofetil, methotrexate and tacrolimus; time to first relapse was similar with or without concomitant treatment | FDA label |
| Anticoagulants | Treatment should not alter anticoagulant management | FDA label |
| Pregnancy and lactation | No human data; registry 1-833-793-0563; human IgG crosses the placenta; discontinue breastfeeding during treatment and for 8 months after the final dose | FDA label |
| Contraindicated | Initiation in patients with unresolved serious Neisseria meningitidis infection | FDA label |
Why a first fill stalls, and the fix
- Prior authorization pending or deniedThe FEP policy below asks for age 18 or older and a positive AQP4 antibody test. It also asks that no other C5 complement inhibitor, such as Soliris, is used for NMOSD at the same time. Your neurologist's office sends the records that show each of these points.
- Your vaccine dates are missingThe REMS requires the infusion site or pharmacy to check and record your meningococcal vaccine status before the first dose. The fix is the office sending the vaccine dates, or the antibiotic prescription if treatment cannot wait.
- The infusion site is not certifiedOnly healthcare settings and pharmacies certified in the ULTOMIRIS and SOLIRIS REMS may dispense it. The office moves the booking to a certified site, which makes it a routing problem and not a denial.
- The prescriber is not enrolled in the REMSBefore each dispense, the site must contact the REMS to confirm the prescriber is certified. A prescriber enrolls by completing the Prescriber Enrollment Form and sending it to the REMS.
- The plan says no after reviewAlexion Access Navigator posts an NMOSD sample letter of medical necessity and a sample appeal letter for your neurologist's office. It also posts a guide to peer-to-peer reviews, a step some offices use before a formal appeal.
- A copay you cannot payWith commercial insurance, the OneSource CoPay Program can bring the cost as low as $0 for eligible patients. Medicare, Medicaid and other government plans are excluded, and OneSource says it can connect those patients with third-party resources.
- You live in Massachusetts or Rhode IslandThe CoPay terms say residents of these 2 states can get help with medicine costs but not with infusion costs. OneSource answers questions about the terms at 1-888-765-4747.
- The renewal after 6 monthsThe FEP policy approves 6 months at first, then 12 months at a time when you have had fewer relapses on Ultomiris. Alexion Access Navigator posts a reauthorization guide for offices. Ask the office when the renewal is due.
Alexion OneSource
- The Alexion OneSource CoPay Program for commercial insurance, as little as $0 for Ultomiris for eligible patients
- The CoPay Program covers eligible out-of-pocket medicine and infusion costs, and annual maximums may apply CoPay terms
- CoPay help is not open to Medicare, Medicaid or other federal- or state-funded plans, and OneSource can point those patients to third-party resources
- Residents of Massachusetts and Rhode Island can get help with medicine costs but not infusion costs, under the CoPay terms CoPay terms
- Enrollment online, by email to OneSource@Alexion.com or by fax at 1-800-420-5150, with interpreters available OneSource enrollment
- Questions answered by phone without enrolling OneSource enrollment
- For the neurologist's office, a Field Reimbursement Manager plus NMOSD sample letters for medical necessity and appeals Alexion Access Navigator
Questions prescribers' offices ask about Ultomiris
What is the Ultomiris dose for NMOSD?
For adults weighing 40kg or more, the October 2026 label gives a weight-based IV loading dose of 2,400mg, 2,700mg or 3,000mg, then a maintenance dose of 3,000mg, 3,300mg or 3,600mg starting 2 weeks later and repeated every 8 weeks. Later doses may occasionally vary within 7 days of the scheduled day, but not the first maintenance dose.
Which vaccines are required before Ultomiris?
Meningococcal vaccines against serogroups A, C, W, Y and B, completed or updated at least 2 weeks before the first dose, per the boxed warning and section 2.2 of the October 2026 label, on the ACIP schedule for complement inhibitor recipients. If urgent therapy is indicated in a patient who is not up to date, the label says to give antibacterial prophylaxis and the vaccines as soon as possible.
What supplemental Ultomiris dose follows plasma exchange or IVIg?
1,200mg to 1,800mg within 4 hours after each plasma exchange or plasmapheresis session, set by weight and the most recent Ultomiris dose, per Table 3 of the October 2026 label. After completion of an IVIg cycle, the supplemental dose is 600mg within 4 hours for every weight band of 40kg or more.
How is a patient switched from Soliris to Ultomiris?
The weight-based Ultomiris loading dose is given at the time of the next scheduled eculizumab dose, per Table 2 of the October 2026 label. The first maintenance dose follows 2 weeks after the loading dose, then every 8 weeks. The Patient Safety Card period after the last Ultomiris dose is 8 months.
What do insurers ask for to approve Ultomiris for NMOSD?
The FEP policy shown here took effect July 1, 2026 and cites the September 2025 label. It asks for age 18 or older, anti-AQP4 antibody positivity, no dual therapy with another C5 complement inhibitor for NMOSD, meningococcal vaccination at least 2 weeks before initiation unless treatment cannot be delayed, and REMS enrollment. It approves 6 months, then 12 months with fewer relapses.
Free email alert
Get an email when the Ultomiris label changes
One email the day the FDA revises the Ultomiris prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Ultomiris only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- ULTOMIRIS (ravulizumab-cwvz) injection, for intravenous use: prescribing information and Medication Guide, revised 10/2026, SPL version 20, effective October 29, 2026 (openFDA record for DailyMed set ID a9a590d9-0217-43c7-908d-e62a71279791), Alexion Pharmaceuticals, via FDA openFDA, 2026-10-29.
- Approved Risk Evaluation and Mitigation Strategies (REMS): Ultomiris and Soliris, BLA 125166 and BLA 761108, REMS last update 06/01/2026, FDA, 2026-06-01.
- Alexion OneSource™ | ULTOMIRIS | Financial Assistance, Alexion Pharmaceuticals, 2026-11-12.
- Alexion OneSource™ | ULTOMIRIS | Fill Out a Start Form, Alexion Pharmaceuticals, 2026-11-12.
- Alexion OneSource™ CoPay Program Terms and Conditions, US/ALL/1223 V1 12/2024, Alexion Pharmaceuticals, 2026-11-12.
- Alexion Access Navigator | Ultomiris NMOSD, Alexion Pharmaceuticals, 2026-11-12.
- 5.85.033 Ultomiris (ravulizumab-cwvz), Blue Cross Blue Shield Federal Employee Program, 2026-07-01.
- BLA 761108/S-046 and BLA 125166/S-455 accelerated approval letter, Ultomiris IgA nephropathy and REMS modification, FDA, 2026-10-21.
- BLA 761108/S-026 and S-031 supplement approval letter, NMOSD and the combined Ultomiris and Soliris REMS, FDA, 2024-03-22.
- An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD (NCT04201262, Study ALXN1210-NMO-307), ClinicalTrials.gov, 2026-11-12.
A reference drawn from the October 29, 2026 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 12, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.